Head-to-head evidence
Paliperidone (Invega) vs Perseris
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone (Invega)
Marketed by Johnson & Johnson
NCT00077714 · Phase 3 · completed
The study was randomized and double-blind, but it enrolled only 12 participants and the registry does not clearly identify a comparator arm. Its primary endpoint was a clinical symptom measure (PANSS), but whether it was met cannot be determined because results are not posted.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
Perseris
Marketed by Indivior Pharmaceuticals, Inc.
NCT02109562 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone (Invega)'s landscape · Perseris's landscape